Danaher Corp. (NYSE: DHR – $77.35) announced it will acquire Swiss dental-implant maker Nobel Biocare Holding AG in a cash deal worth about $2.1 billion, to strengthen its position in the dental market. Nobel Biocare is a world leader in the field of innovative implant-based dental restorations – from single tooth to fully edentulous indications. Danaher said it will pay the equivalent of $$18.20 a share in a transaction expected to close by late 2014 or early 2015. Danaher also said Nobel Biocare’s board is recommending shareholders accept the offer, and that the Zurich-based company would operate as a stand-alone business within Danaher’s existing $2.2 billion dental platform. This acquisition is the largest for Danaher since the Beckman-Coulter deal it made back in 2012. The all cash purchase is expected to widen Danaher’s market presence in the global dental industry and allow Nobel Biocare to accelerate its strategic objectives and future growth. As of the end of the third quarter, DHR had over $3.3 billion in cash on hand with another $8 billion in available credit lines, and was ripe for a long-awaited major acquisition. While in the short-term Danaher’s shares will continue to fight economic headwinds in some of its diversified business segments such as industrial technologies and environmental, the long-term outlook appears positive and well-defined.